Roche, Lilly drugs chosen for Alzheimer's prevention trial

Oct 10 (Reuters) - Roche Holding AG's experimentaldrug gantenerumab and Eli Lilly & Co's solanezumab havebeen chosen to be tested in a high-profile global Alzheimer'sdisease prevention trial, and a second Lilly medicine is beingconsidered for potential inclusion in the study, WashingtonUniversity said on Wednesday.

The St. Louis-based University said the trial, expected tobegin in early 2013, will enroll 160 patients with inheritedgene mutations that typically lead to Alzheimer's disease at ayoung age.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick)

((ransdell.pierson@thomsonreuters.com)(646 223 6030))